Nothing Special   »   [go: up one dir, main page]

Savva et al., 2024 - Google Patents

Recent Advancements in the Atopic Dermatitis Mechanism

Savva et al., 2024

View HTML
Document ID
4802223081213557435
Author
Savva M
Papadopoulos N
Gregoriou S
Katsarou S
Papapostolou N
Makris M
Xepapadaki P
Publication year
Publication venue
Frontiers in Bioscience-Landmark

External Links

Snippet

Atopic dermatitis (AD) is a recurrent, chronic, inflammatory, itchy skin disorder that affects up to 20% of the pediatric population and 10% of the adult population worldwide. Onset typically occurs early in life, and although cardinal disease features are similar across all …
Continue reading at www.imrpress.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material

Similar Documents

Publication Publication Date Title
Li et al. Update on the pathogenesis and therapy of atopic dermatitis
Luger et al. Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents
Facheris et al. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment
Rodrigues et al. JAK/STAT inhibitors for the treatment of atopic dermatitis
Kaufman et al. Atopic dermatitis in diverse racial and ethnic groups—variations in epidemiology, genetics, clinical presentation and treatment
Heimall et al. Filaggrin mutations and atopy: consequences for future therapeutics
Marek-Jozefowicz et al. The brain–skin axis in psoriasis—psychological, psychiatric, hormonal, and dermatological aspects
Dainichi et al. The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis
David Boothe et al. Atopic dermatitis: pathophysiology
Renert-Yuval et al. What’s new in atopic dermatitis
Lee et al. Current and emerging therapies for hand eczema
Singh et al. IL-31-driven skin remodeling involves epidermal cell proliferation and thickening that lead to impaired skin-barrier function
Huang et al. Severe atopic dermatitis in children
D’Erme et al. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy
Pugliarello et al. Phenotypes of atopic dermatitis
Luo et al. Akkermansia muciniphila prevents cold-related atrial fibrillation in rats by modulation of TMAO induced cardiac pyroptosis
Fostini et al. Prurigo nodularis: an update on etiopathogenesis and therapy
Savva et al. Recent Advancements in the Atopic Dermatitis Mechanism
Rauen et al. Costello and cardio‐facio‐cutaneous syndromes: Moving toward clinical trials in RASopathies
Zellweger et al. IgE‐associated allergic disorders: recent advances in etiology, diagnosis, and treatment
Dębińska New treatments for atopic dermatitis targeting skin barrier repair via the regulation of FLG expression
Hülpüsch et al. A new era of atopic eczema research: advances and highlights
Zhang et al. Methamphetamine disturbs gut homeostasis and reshapes serum metabolome, inducing neurotoxicity and abnormal behaviors in mice
Awosika et al. Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis
Lossius et al. Shifts in the skin microbiota after UVB treatment in adult atopic dermatitis